Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm
- PMID: 19213661
- DOI: 10.3816/CGC.2009.n.001
Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm
Comment on
-
Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis.Clin Genitourin Cancer. 2009 Jan;7(1):11-9. doi: 10.3816/CGC.2009.n.002. Clin Genitourin Cancer. 2009. PMID: 19213662
-
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.Clin Genitourin Cancer. 2009 Jan;7(1):20-3. doi: 10.3816/CGC.2009.n.003. Clin Genitourin Cancer. 2009. PMID: 19213663 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical